News

GRP Hires Mitchel Allen-Rivera as new Executive Vice President of Business Development

The Greater Richmond Partnership (“GRP”), the lead regional economic development organization serving the City of Richmond and counties of Chesterfield, Hanover and Henrico in Virginia, announces that Mitchel Allen-Rivera is the new Executive Vice President of Business Development.

“I am thrilled to welcome Mitchel to Greater Richmond to lead business development,” said Jennifer Wakefield, President and CEO of the Greater Richmond Partnership. “He is a rockstar economic development professional with a stellar reputation and has repeatedly been recognized among the best in the industry.”

Allen-Rivera is relocating to Greater Richmond, Va., from Phoenix, Ariz., where he has worked as the Senior Vice President of Business Development for the Greater Phoenix Economic Council (GPEC) for nearly a decade in roles of increasing responsibility. In addition to his time at GPEC, he worked at the local level in the City of Chandler, Ariz., and as a manager in the financial services industry.

“I am truly honored to be joining such an exceptional team of professionals under Jennifer Wakefield’s leadership,” said Allen-Rivera. “Richmond is an amazing community full of talent and I am eager to contribute to the region’s future development.”

Allen-Rivera has a bachelor’s degree in communication from Arizona State University and is currently pursuing a master of business administration (MBA) from the University of Denver. He has been recognized twice among the Top 50 economic developers in North America by Consultant Connect, been named as a top 40 under 40 professional in economic development by Development Counsellors International and the International Economic Development Council and as Economic Developer of the Year by the Arizona Association for Economic Development.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and